Nitin Sood - Aug 7, 2023 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief Commercial Officer, MRD
Signature: /s/ Nitin Sood by Stacy L Taylor, Attorney-in-Fact
Stock symbol: ADPT
Transactions as of: Aug 7, 2023
Transactions value $: -$107,318
Form type: 4
Date filed: 8/8/2023, 04:53 PM
Previous filing: Mar 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Sale	-$38.3K	-5.65K	-2.45%	$6.78	225K	Aug 7, 2023	Direct	F1
transaction	ADPT	Common Stock	Sale	-$69K	-10.6K	-4.68%	$6.54	215K	Aug 8, 2023	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.
F3	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.